Hemodynamic effects of celiprolol in patients with ischemic and non-ischemic cardiomyopathy

In this study, the effect of celiprolol (beta-l-antagonist with beta-2-agon istic activity) on hemodynamic and electrocardiographic parameters of patie nts with congestive heart failure due to ischemic (iCMP) and non-ischemic ( niCMP) origin should be evaluated. Sixteen patients were included into the study, nine with iCMP, seven with niCMP. All patients were investigated by radionuclide ventriculography (Tc-99m), right heart floating catheterizatio n, and late potential analysis and measurement of heart rate variability. A ll patients received 200 mg celiprolol after a 3-day period of 100 mg celip rolol/day. All patients showed, after a follow-up period of 3 months, a sig nificant improvement of the left ventricular ejection fraction. The changes of hemodynamic parameters were more pronounced in patients with niCMP. Hea rt rate did not decrease in patients with niCMP. A 3-month therapy with cel iprolol as an additional therapy to a preexisting heart failure therapy lea ds to a significant improvement of the ejection fraction in patients with c ongestive heart failure. Patients with niCMP seemed to profit more from thi s additional beta-blocking therapy. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.